Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data

Recently, the treatment landscape for chronic lymphocytic leukemia (CLL) has changed dramatically due to the development of drugs targeting proteins in the B cell antigen receptor (BCR) pathway. Acalabrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, was recently FDA approved fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaac, Krista, Mato, Anthony R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090151/
https://www.ncbi.nlm.nih.gov/pubmed/32256115
http://dx.doi.org/10.2147/CMAR.S219570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090151/
https://www.ncbi.nlm.nih.gov/pubmed/32256115
http://dx.doi.org/10.2147/CMAR.S219570

Ejemplares similares